Abstract:
Release Date: October, 2008
Expiration Date: October 31, 2009
Estimated Time to Complete Activity: 1.25 hours
60 minutes in length
Sponsors:
This program is jointly sponsored by Postgraduate Institute for Medicine and IMPACt, Inc.
Contact Postgraduate Institute for Medicine
Commercial Support:
This activity is supported by Genentech, Inc. and Eli Lilly and Company.
Description:
Recommended changes to the current NSCLC TNM Staging system are expected to be adopted in 2009. Adoption of the new stage descriptors and groupings will result in the stage shifting of thousands of patients a year with the goals of providing more accurate prognosis and improved alignment of treatment choices than under the current system. This program summarizes the proposed changes and applies them to case based scenarios.
Learning Objectives:
Upon completion of this activity, participants will be able to:
1. Outline changes to the TNM staging system for lung cancer as proposed by the IASLC
2. Describe how the proposed TNM system changes will impact the accurate staging and therefore the prognosis and appropriate treatment for patients with lung cancer
3. Apply the proposed TNM changes to the staging and appropriate treatment recommendations for the case studies presented
Target Audience:
This activity has been designed to meet the educational needs of medical oncologists, radiation oncologists and surgical oncologists involved in the care of patients with lung cancer.
Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and IMPACt, Inc. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Agenda:
This program will be 60 minutes in length.
• Introduction
• Overview and impact of the proposed TNM Staging changes
• Case Studies - Cases will be selected to illustrate the potential stage shifting that will occur in specific types of patients as well as the resulting determination of appropriate therapy
• Q&A
• Summary and Conclusions
Faculty:
Eric Vallières, MD, FRCSC (Course Director)
Surgical Director of the Lung Cancer Program
Swedish Cancer Institute
Gregory M.M. Videtic, MD, CM, FRCPC
Residency Program Director
Department of Radiation Oncology
Cleveland Clinic Foundation
Mark A. Socinski, MD
Professor of Medicine
Multidisciplinary Thoracic Oncology Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Eric Vallieres, MD, FRCSC
Consulting Fees: Eli Lilly, Genentech
Mark A. Socinski, MD
Fees for Non-CME Services: Eli Lilly, Genentech, sanofi-aventis
Contracted Research: Abraxis, Celegene, Eli Lilly, Genentech, Pfizer, sanofi-aventis
Gregory M. W. Videtic, MD, CM, CRCPC
No significant financial relationship with any commercial entity related to this activity
The following PIM and IMPACt, Inc. clinical content reviewers, Linda Graham, RN; Jan Hixon, RN, Jan Schultz, RN, BSN, MSN, Trace Hutchison, PharmD and Scott McMahon hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity or any amount during the past 12 months.
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), IMPACt, Inc., Genentech, Inc. and Eli Lilly and Company, do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, IMPACt, Inc., Genentech, Inc. and Eli Lilly and Company. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information.